Kymera Therapeutics, Inc. (KYMR) | Stock price, performance, AI analysis | Thematic | AI powered fundamental research and development platform

Loading...

Research a topic Stock screener Find companies

Search for securities Load an existing portfolio Backtest

How to use About us Blog

|

Research a topic Stock screener Find companies

Search for securities Load an existing portfolio Backtest

How to use About us Blog

Follow our journey and product updates

Product

Research a topic Stock screener Find companies Search for securities Load an existing portfolio Backtest

Learn

Thematic overview Develop asset-backed products Company evaluations Backtesting and benchmarking Thematic branded indices Build investment strategies with crypto

Company

How to use About us Blog

Team Research

There is currently no saved research for this page.

Kymera Therapeutics, Inc. (KYMR)

Add to research

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation

Company performance

Add to research

Current Price

as of Mar 20, 2025

$33.21

P/E Ratio

N/A

Market Cap

$2.16B

Description

Add to research

Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.

Metrics

Add to research

Overview

HQWatertown, MA
SectorHealth Technology
IndustryBiotechnology
TickerKYMR
Price$33.21-1.95%

Trading Information

Market cap$2.16B
Float83.09%
Average Daily Volume (1m)772,901
Average Daily Volume (3m)564,578
EPS-$2.98

Company

Revenue$47.07M
Rev growth (1yr)-40.11%
Net income-$223.86M
Gross margin84.34%
EBITDA margin-529.69%
EBITDA-$249.34M

EV$2.62B
EV/Revenue55.62
P/EN/A
P/S52.94
P/B2.58
Debt/Equity10.50

Documents

Add to research

SEC Filings

8-K (2025-03-03)

8-K (2025-02-27)

8-K (2025-01-14)

8-K (2024-10-31)

8-K (2024-08-20)

8-K (2024-08-07)

8-K (2024-07-08)

8-K (2024-06-20)

8-K (2024-05-02)

8-K (2024-04-01)

8-K (2024-02-22)

8-K (2024-01-05)

8-K (2024-01-04)

8-K (2023-11-02)

8-K (2023-08-03)

8-K (2023-06-16)

8-K (2023-05-22)

8-K (2023-05-04)

8-K (2023-03-10)

8-K (2023-02-27)

8-K (2023-02-23)

8-K (2023-01-10)

10-Q (2024-10-31)

10-Q (2024-08-07)

10-Q (2024-05-02)

10-Q (2023-11-02)

10-Q (2023-08-03)

10-Q (2023-05-04)

10-K (2025-02-27)

10-K (2024-02-22)

10-K (2023-02-23)

Earnings Calls

Earnings Report 2024Q4

Earnings Report 2024Q3

Earnings Report 2024Q2

Earnings Report 2024Q1

Earnings Report (2023-11-04)

Earnings Report (2023-08-06)

Factset

Factset Business Description

Factset Street Account

Wells Fargo Securities upgrades ARVN; downgrades KYMR (2023-12-19T11:52:27Z)

StreetAccount Earnings Call Q&A Summary: Kymera Therapeutics Q3 ($ 12.14, +0.58) (2023-11-02T18:51:37Z)

Kymera Therapeutics to present new data from phase 1 trial of KT-333 at ASH ($11.55, 0.00) (2023-11-02T13:06:13Z)

Kymera Therapeutics reports Q3 EPS ($0.90) vs FactSet ($0.64) [16 est, ($0.90)-0.42] ($11.55, 0.00) (2023-11-02T11:13:57Z)

Kymera Therapeutics notes publication of Phase 1 trial results for KT-474 (SAR444656) in Nature Medicine ($14.07, -0.45) (2023-11-13T16:01:41Z)

Kymera Therapeutics announces first patient dosed in phase 2 trial of KT-474 in Hidradenitis Suppurativa ($11.51, 0.00) (2023-10-27T11:07:30Z)

Ask a question

New feature

Thematic Research

View all of your research in one place. Toggle open the floating actions menu and click Open research sidebar to view your saved research for the current page.